Kenneth J Smith1, Angela R Wateska2, Mary Patricia Nowalk3, Mahlon Raymund3, Bruce Y Lee2, Richard K Zimmerman3. 1. Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. Electronic address: smitkj2@UPMC.EDU. 2. Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. 3. Department of Family Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Abstract
BACKGROUND: The 13-valent pneumococcal conjugate vaccine (PCV13) is approved by the U.S. Food and Drug Administration for adults, but its role in older adults is unclear. PURPOSE: To compare PCV13 strategies to currently recommended vaccination strategies in adults aged ≥65 years. METHODS: Using a Markov model, the cost effectiveness of PCV13 and the 23-valent pneumococcal polysaccharide vaccine (PPSV23), alone or in combination, was estimated, in adults aged either 65 years or 75 years. No prior vaccination, prior vaccination, and vaccine hyporesponsiveness scenarios were examined. Pneumococcal disease rates, indirect childhood PCV13 effects, and costs were estimated using CDC Active Bacterial Core surveillance data and U.S. national databases. An expert panel estimated vaccine-related protection. A societal perspective was taken and outcomes were discounted 3% per year. RESULTS: In those aged 65 years, single-dose PCV13 cost $11,300 per quality-adjusted life-year (QALY) gained compared to no vaccination; at ages 65 and 80 years, PCV13 cost $83,000/QALY. In those aged 75 years, single-dose PCV13 cost $62,800/QALY gained. PPSV23 cost more and was less effective than PCV13. Results were sensitive to varying vaccine effectiveness and indirect effect estimates. In hyporesponsiveness scenarios, cost-effectiveness ratios increased by 37%-78% for single-dose strategies and 29%-35% for multiple-dose strategies. CONCLUSIONS: Single-dose PCV13 strategies are likely to be economically reasonable in older adults.
BACKGROUND: The 13-valent pneumococcal conjugate vaccine (PCV13) is approved by the U.S. Food and Drug Administration for adults, but its role in older adults is unclear. PURPOSE: To compare PCV13 strategies to currently recommended vaccination strategies in adults aged ≥65 years. METHODS: Using a Markov model, the cost effectiveness of PCV13 and the 23-valent pneumococcal polysaccharide vaccine (PPSV23), alone or in combination, was estimated, in adults aged either 65 years or 75 years. No prior vaccination, prior vaccination, and vaccine hyporesponsiveness scenarios were examined. Pneumococcal disease rates, indirect childhood PCV13 effects, and costs were estimated using CDC Active Bacterial Core surveillance data and U.S. national databases. An expert panel estimated vaccine-related protection. A societal perspective was taken and outcomes were discounted 3% per year. RESULTS: In those aged 65 years, single-dose PCV13 cost $11,300 per quality-adjusted life-year (QALY) gained compared to no vaccination; at ages 65 and 80 years, PCV13 cost $83,000/QALY. In those aged 75 years, single-dose PCV13 cost $62,800/QALY gained. PPSV23 cost more and was less effective than PCV13. Results were sensitive to varying vaccine effectiveness and indirect effect estimates. In hyporesponsiveness scenarios, cost-effectiveness ratios increased by 37%-78% for single-dose strategies and 29%-35% for multiple-dose strategies. CONCLUSIONS: Single-dose PCV13 strategies are likely to be economically reasonable in older adults.
Authors: John Hansen; Steven Black; Henry Shinefield; Thomas Cherian; Jane Benson; Bruce Fireman; Edwin Lewis; Paula Ray; Janelle Lee Journal: Pediatr Infect Dis J Date: 2006-09 Impact factor: 2.129
Authors: Lisa A Jackson; Kathleen M Neuzil; Moon H Nahm; Cynthia G Whitney; Onchee Yu; Jennifer C Nelson; Pat T Starkovich; Maya Dunstan; Barbara Carste; David K Shay; James Baggs; George M Carlone Journal: Vaccine Date: 2007-03-12 Impact factor: 3.641
Authors: Carolyn M Greene; Moe H Kyaw; Susan M Ray; William Schaffner; Ruth Lynfield; Nancy L Barrett; Christine Long; Ken Gershman; Tamar Pilishvili; Angela Roberson; Elizabeth R Zell; Cynthia G Whitney; Nancy M Bennett Journal: Clin Infect Dis Date: 2006-06-09 Impact factor: 9.079
Authors: Catherine A Lexau; Ruth Lynfield; Richard Danila; Tamara Pilishvili; Richard Facklam; Monica M Farley; Lee H Harrison; William Schaffner; Arthur Reingold; Nancy M Bennett; James Hadler; Paul R Cieslak; Cynthia G Whitney Journal: JAMA Date: 2005-10-26 Impact factor: 56.272
Authors: Carlos G Grijalva; J Pekka Nuorti; Patrick G Arbogast; Stacey W Martin; Kathryn M Edwards; Marie R Griffin Journal: Lancet Date: 2007-04-07 Impact factor: 79.321
Authors: L A Jackson; P Benson; V P Sneller; J C Butler; R S Thompson; R T Chen; L S Lewis; G Carlone; F DeStefano; P Holder; T Lezhava; W W Williams Journal: JAMA Date: 1999-01-20 Impact factor: 56.272
Authors: Jane E Sisk; William Whang; Jay C Butler; Vishnu-Priya Sneller; Cynthia G Whitney Journal: Ann Intern Med Date: 2003-06-17 Impact factor: 25.391
Authors: Andrew J Leidner; Neil Murthy; Harrell W Chesson; Matthew Biggerstaff; Charles Stoecker; Aaron M Harris; Anna Acosta; Kathleen Dooling; Carolyn B Bridges Journal: Vaccine Date: 2018-12-04 Impact factor: 3.641
Authors: Sevan Dirmesropian; James G Wood; C Raina MacIntyre; Philippe Beutels; Anthony T Newall Journal: Pharmacoeconomics Date: 2016-08 Impact factor: 4.981